ENETS Position Statement on Somatostatin Analogue Management in Advanced Neuroendocrine Neoplasms

The European Neuroendocrine Tumor Society (ENETS) position statement evaluates unresolved clinical scenarios regarding the use of somatostatin analogues (SSAs) beyond their established indications in functioning neuroendocrine tumours (NETs) and grade 1 to 2 gastro-entero-pancreatic NETs with Ki-67 levels up to 10%. Addressing 10 clinical questions, the guidance reviews evidence on dose intensification, expanded tumour grades, rare presentations, adjuvant therapy, and predictive biomarkers.

Available evidence indicates that SSA dose-intensification—via dose escalation or interval shortening following progression—primarily provides hormonal symptom control and temporary disease stabilization in selected individuals, while objective tumour responses remain uncommon. Anti-proliferative activity may also occur in certain grade 2 NETs with Ki-67 indices greater than 10%, though therapeutic activity diminishes as proliferative rates increase and remains limited in grade 3 tumours. Evidence regarding pulmonary carcinoids, Multiple Endocrine Neoplasia type 1 (MEN1)-related pancreatic NETs, and uncommon somatostatin receptor (SSTR)-positive neoplasms remains heterogeneous and predominantly derived from small or non-randomized studies.

Following complete surgical resection, routine adjuvant SSA administration is not supported by current evidence, although retrospective studies suggest a potential risk reduction in selected patients with resected pancreatic NETs at high recurrence risk. Furthermore, while quantitative SSTR imaging, tissue SSTR2 expression, and circulating molecular markers show promise for patient selection, none are currently validated for routine predictive clinical use. Emerging SSTR-directed agents with distinct receptor-binding profiles may broaden future management strategies pending prospective clinical evaluation.